SCHEMBL7189912

SCHEMBL7189912

CP(=O)(C(=O)c1c(Cl)cccc1Cl)c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
MAPT P10636 3/20 0.42
PTK2B Q14289 1/20 0.42
ESR1 P03372 1/20 0.40
FEN1 P39748 1/20 0.40
SMO Q99835 1/20 0.39
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
KMT2A Q03164 1/20 0.39
PBRM1 Q86U86 1/20 0.38
CA2 P00918 1/20 0.38
CA4 P22748 1/20 0.38
CA5A P35218 1/20 0.38
TAS1R3 Q7RTX0 1/20 0.37
TAS1R1 Q7RTX1 1/20 0.37
TAS1R2 Q8TE23 1/20 0.37
KDM4E B2RXH2 1/20 0.37
APAF1 O14727 1/20 0.37
TDP2 O95551 1/20 0.37
NSD2 O96028 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7189033 0.90 TYK2 (0.44) ALDH1A1MAPTPTK2BKMT2ATYK2
SCHEMBL7185616 0.86 CA12 (0.47) ALDH1A1MAPTPTK2BMEN1KMT2A
SCHEMBL67557 0.81 ALDH1A1 (0.47) ALDH1A1MAPTPTK2BFEN1KMT2A
SCHEMBL58730 0.81 ALDH1A1 (0.47) ALDH1A1MAPTPTK2BFEN1KMT2A
SCHEMBL7175016 0.80 ESR1 (0.41) ALDH1A1MAPTESR1MEN1KMT2A
SCHEMBL6368591 0.80 MAPT (0.46) ALDH1A1MAPTPTK2BFEN1KMT2A
SCHEMBL69221 0.79 ALDH1A1 (0.52) ALDH1A1MAPTPTK2BFEN1TAS1R3
SCHEMBL2771878 0.78 MAPT (0.42) ALDH1A1MAPTPTK2BFEN1MEN1
SCHEMBL7188567 0.78 ALDH1A1 (0.40) ALDH1A1MAPTPTK2BFEN1PBRM1
SCHEMBL7182200 0.78 ALDH1A1 (0.40) ALDH1A1MAPTPTK2BFEN1SMO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 ALDH1A1 3416/4885MAPT 4870/4885PTK2B 1875/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 ALDH1A1 3984/4885MAPT 4859/4885PTK2B 2406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.